What is HSDD?

Categories: , , , ,

What is HSDD?

Hypoactive sexual desire dysfunction (HSDD) is an extremely common medical condition that causes distress resulting from a low sexual desire.

Clinical data indicates that 7 in 10 women (aged 40-64) presented with low sexual desire, and 1 in 3 women (aged 40-64) reported low desire with distress (HSDD)2.

Engaging your Doctor

We understand that this maybe a sensitive subject. Many women feel discomfort or embarrassment which contributes to their unwillingness to seek treatment (only 20% of women with HSDD actively consult with their doctor).

In order to facilitate discussing this subject with your physician please download and answer the Screener Questionnaire and present it to your doctor.

HSDD Screener

 

 

Doctors who are members of the Australasian Menopause Society (AMS) have a special interest in women’s health in midlife and menopause, and the promotion of healthy ageing.

To help you find a doctor who is right for you the AMS search feature Find an AMS doctor may be useful.

 

  1. Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women J Sex Med Worsley R et al. J Sex Med 14:675-686

Latest News


Mindfulness May Help Lower Sexual Distress in Older Women With Low Libido Mindfulness May Help Lower Sexual Distress in Older Women With Low Libido

International Society For Sexual Medicine Mindfulness May Help Lower Sexual Distress in Older Women With Low Libido    

NEW IMS Symposium with Dr James Simon & Sharon Parish NEW IMS Symposium with Dr James Simon & Sharon Parish

Sexual Health and Treatment for Women: Fact, Fiction, the Future. At the International Menopause Society’s 19th World Congress on Menopause to be held 19th – 22nd October 2024 in… Continue Reading →

INTERNATIONAL RECOGNITION PROCEDURE OFFERS HOPE FOR UK’S POSTMENOPAUSAL WOMEN. INTERNATIONAL RECOGNITION PROCEDURE OFFERS HOPE FOR UK’S POSTMENOPAUSAL WOMEN.

Hypoactive Sexual Desire Dysfunction (HSDD) Perth, Australia: Lawley Pharmaceuticals, via UK-based commercial partner, Andro Pharmaceuticals Ltd, today submitted a Marketing Authorisation Application (MAA) for… Continue Reading →